Is it time to take profits in CSL Limited?

Biotechnology company CSL Limited (ASX:CSL) has had a stellar run after releasing its half yearly earnings report on February 14. After closing Friday's trading session at $165.57, the company's valuation of around 36 times projected FY18 earnings appears to be getting stretched. Is it time for investors to take profits? 

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Biotechnology company CSL Limited (ASX: CSL) has had a stellar run after releasing its half yearly earnings report on February 14. The stock is up 16% since then, bringing the annual gain to about 33%.

After closing Friday's trading session at $165.57, the company's valuation of around 36 times projected FY18 earnings appears to be getting stretched. Is it time for investors to take profits?

Market beat drives record highs

CSL delivered another exceptional operational result for the 6 months ended 31 December 2017. Net profit after tax (NPAT) increased by 35% to US$1,086 million (up 31% at constant currency) with earnings per share rising 36% to US$2.40 (up 32% at constant currency) for the period.

Revenue for the period grew by 12.8% to US$4,147 million with the notable standouts being specialty products and Seqirus. Specialty revenues rose 21.9% to US$717 million due to the successful launch of HAEGARDA and a 32% rise on the prior corresponding period (pcp) for Kcentra in the U.S. A particularly severe strain of influenza in the Northern Hemisphere was the catalyst in revenues for Seqirus increasing 27.6% to US$791 million.

CSL's bottom line result and full year guidance raise beat market expectations and has propelled the stock to a record high of $167.66 on March 12. The main driver for the beat was the surge in earnings before interest and tax (EBIT) margins from 29.8% to 35.6%. Group margins improved materially due to a shift in Immunoglobulin mix, a transition of Haemophilia portfolio, specialty products growth, uneven expenditure timing and a strong seasonal performance from Seqirus which delivered a segment profit of US$185 million compared to the US$3 million loss in the pcp.

FY18 guidance was for NPAT to be within the range of approximately US$1,550 to US$1,600 million at constant currency. Net profit is skewed heavily towards the first half due to the seasonality of Seqirus' influenza business and the planned increase in research & development expenses.

Foolish takeaway

CSL remains one of the best companies on the Australian market, particularly in the large cap space and its track record in growing earnings over the long term warrants a premium to the general market. With the stock trading at 36 times forward earnings for FY18, I think most of the growth is priced in for the near term. However, for long term orientated investors I wouldn't take profits just yet. The underlying business is still growing strongly which should lead to higher earnings and share price appreciation over the long term.

Motley Fool Contributor Tim Katavic owns shares of CSL Limited. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on ⏸️ Investing

Close up of baby looking puzzled
Retail Shares

What has happened to the Baby Bunting (ASX:BBN) share price this year?

It's been a volatile year so far for the Aussie nursery retailer. We take a closer look

Read more »

woman holds sign saying 'we need change' at climate change protest
ETFs

3 ASX ETFs that invest in companies fighting climate change

If you want to shift some of your investments into more ethical companies, exchange-traded funds can offer a good option

Read more »

a jewellery store attendant stands at a cabinet displaying opulent necklaces and earrings featuring diamonds and precious stones.
⏸️ Investing

The Michael Hill (ASX: MHJ) share price poised for growth

Investors will be keeping an eye on the Michael Hill International Limited (ASX: MHJ) share price today. The keen interest…

Read more »

ASX shares buy unstoppable asx share price represented by man in superman cape pointing skyward
⏸️ Investing

The Atomos (ASX:AMS) share price is up 15% in a week

The Atomos (ASX: AMS) share price has surged 15% this week. Let's look at what's ahead as the company build…

Read more »

Two people in suits arm wrestle on a black and white chess board.
Retail Shares

How does the Temple & Webster (ASX:TPW) share price stack up against Nick Scali (ASX:NCK)?

How does the Temple & Webster (ASX: TPW) share price stack up against rival furniture retailer Nick Scali Limited (ASX:…

Read more »

A medical researcher works on a bichip, indicating share price movement in ASX tech companies
Healthcare Shares

The Aroa (ASX:ARX) share price has surged 60% since its IPO

The Aroa (ASX:ARX) share price has surged 60% since the Polynovo (ASX: PNV) competitor listed on the ASX in July.…

Read more »

asx investor daydreaming about US shares
⏸️ How to Invest

How to buy US shares from Australia right now

If you have been wondering how to buy US shares from Australia to gain exposure from the highly topical market,…

Read more »

⏸️ Investing

Why Fox (NASDAQ:FOX) might hurt News Corp (ASX:NWS) shareholders

News Corporation (ASX: NWS) might be facing some existential threats from its American cousins over the riots on 6 January

Read more »